FedEx Express, a subsidiary of FedEx Corp. (NYSE: FDX) and one of the world’s largest express transportation companies, has been recognized for being the “Best Clinical Trial Logistics Provider” and for providing the “Best Last Mile Implementation” at the annual IMAPAC Asia Pacific Bioprocessing Excellence Awards 2022. These two awards recognize the exceptional healthcare expertise, services and technologies at FedEx that facilitate biomanufacturing excellence at enhanced speed, reduced costs and superior quality. The Asia Pacific Bioprocessing Excellence Awards 2022 was held in conjunction with the sixth Annual Biologistics World Asia 2022.
FedEx was shortlisted among the top five various logistics providers for both awards, with FedEx emerging as the winner for the two categories. Nominations were vetted by IMAPAC’s scientific board who are experts in the respective fields.
“This recognition is testament to our industry leading tech-led solutions that provide the precision and reliability needed to move temperature sensitive and time-critical shipments. We are proud of our advanced cold-chain solutions that have clearly gained the trust and recognition of our healthcare customers. During the COVID-19 pandemic, end-to-end logistics support has become even more important,” said Kawal Preet, president of Asia Pacific, Middle East and Africa (AMEA) at FedEx Express, “With the Asia Pacific region being the world’s fastest-growing clinical trial market[1], and the AMEA region estimated to be an $8.4 billion market for clinical trials by 2027[2], we will continue to innovate our healthcare solutions to support the rapid growth in this sector.”
“We are honoured to have our healthcare leadership recognized. FedEx is committed to pushing the boundaries of what the logistics industry can do for the healthcare sector through continuous innovation to enhance our solutions,” said Audrey Cheong, regional vice president, South East Asia, FedEx Express. “This award affirms our work as an organisation that has innovated and upheld the highest level of standards in Clinical Trial Logistics and Last Mile logistics solutions.”
The award comes amidst global recovery from the pandemic, during which FedEx teams have supported customers and the broader community through innovative cold chain technology that facilitates the delivery of key essential medical items. One example is the industry-first SenseAware, a sensory device that travels with high-value, time, temperature, and shock-sensitive shipments, enabling customers full access and round-the-clock visibility on the condition of a package enroute to its destination. For its leading role in protecting shipment integrity and keeping vaccines moving across the globe, FedEx was also named “Asia’s Best 3PLs for Vaccines” at the 2021 Asia Pacific Vaccine Excellence Awards.
[1] https://finance.yahoo.com/news/clinical-trials-market-projected-reach-102400400.html
[2] A combined value of the APAC ($6.2 billion) and the MEA region ($2.1 billion) by 2027 https://www.marketdataforecast.com/market-reports/apac-clinical-trials-market
FedEx was shortlisted among the top five various logistics providers for both awards, with FedEx emerging as the winner for the two categories. Nominations were vetted by IMAPAC’s scientific board who are experts in the respective fields.
“This recognition is testament to our industry leading tech-led solutions that provide the precision and reliability needed to move temperature sensitive and time-critical shipments. We are proud of our advanced cold-chain solutions that have clearly gained the trust and recognition of our healthcare customers. During the COVID-19 pandemic, end-to-end logistics support has become even more important,” said Kawal Preet, president of Asia Pacific, Middle East and Africa (AMEA) at FedEx Express, “With the Asia Pacific region being the world’s fastest-growing clinical trial market[1], and the AMEA region estimated to be an $8.4 billion market for clinical trials by 2027[2], we will continue to innovate our healthcare solutions to support the rapid growth in this sector.”
“We are honoured to have our healthcare leadership recognized. FedEx is committed to pushing the boundaries of what the logistics industry can do for the healthcare sector through continuous innovation to enhance our solutions,” said Audrey Cheong, regional vice president, South East Asia, FedEx Express. “This award affirms our work as an organisation that has innovated and upheld the highest level of standards in Clinical Trial Logistics and Last Mile logistics solutions.”
The award comes amidst global recovery from the pandemic, during which FedEx teams have supported customers and the broader community through innovative cold chain technology that facilitates the delivery of key essential medical items. One example is the industry-first SenseAware, a sensory device that travels with high-value, time, temperature, and shock-sensitive shipments, enabling customers full access and round-the-clock visibility on the condition of a package enroute to its destination. For its leading role in protecting shipment integrity and keeping vaccines moving across the globe, FedEx was also named “Asia’s Best 3PLs for Vaccines” at the 2021 Asia Pacific Vaccine Excellence Awards.
[1] https://finance.yahoo.com/news/clinical-trials-market-projected-reach-102400400.html
[2] A combined value of the APAC ($6.2 billion) and the MEA region ($2.1 billion) by 2027 https://www.marketdataforecast.com/market-reports/apac-clinical-trials-market
